13575-74-1

Basic information

• Product Name: 4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID
• Synonyms: 4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID;LABOTEST-BB LT00452952;Nsc286140;3,4-DiMethoxybenzenebutanoic Acid;4-(3,4-Dimethoxyphenyl)butyric acid 99%
• CAS NO: 13575-74-1
• Molecular Formula: C₁₂H₁₆O₄
• Molecular Weight: 224.25
• Product Categories: C11 to C12;Carbonyl Compounds;Carboxylic Acids;Aromatics;Intermediates
• Mol File: 13575-74-1.mol
• Article Data: 19

Chemical Properties

• Melting Point: 62-63 °C(lit.)
• Boiling Point: 210 °C6 mm Hg(lit.)
• Flash Point: 210°C/6mm
• Appearance: /
• Density: 1.1697 (rough estimate)
• Vapor Pressure: 3.47E-06mmHg at 25°C
• Refractive Index: 1.5130 (estimate)
• PKA: 4.74±0.10(Predicted)
• CAS DataBase Reference: 4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID(CAS DataBase Reference)
• NIST Chemistry Reference: 4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID(13575-74-1)
• EPA Substance Registry System: 4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID(13575-74-1)

Safety Data

• Hazard Codes: Xi
• Statements: 36
• Safety Statements: 26
• WGK Germany: 3
• Hazardous Substances Data: 13575-74-1(Hazardous Substances Data)

Usage

Description

4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID is a butyrate analogue characterized by its presence of two methoxy groups on the phenyl ring, which contributes to its unique chemical properties. It is known for its effects on apoptosis, proliferation, and histone deacetylase (HDAC) activity, making it a compound of interest in various scientific and medical applications.

Uses

Used in Pharmaceutical Applications:
4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID is used as a pharmaceutical agent for its effects on apoptosis, proliferation, and HDAC activity in HT-29 colorectal cancer cells. This suggests its potential use in the development of treatments for colorectal cancer and possibly other types of cancer.
Used in Chemical Synthesis Studies:
4-(3,4-DIMETHOXYPHENYL)BUTYRIC ACID is used as a key compound in chemical synthesis studies. Its unique structure and properties make it a valuable building block for the development of new molecules with potential applications in various industries, including pharmaceuticals, materials science, and agrochemicals.

InChI:InChI=1/C12H16O4/c1-15-10-7-6-9(8-11(10)16-2)4-3-5-12(13)14/h6-8H,3-5H2,1-2H3,(H,13,14)

Upstream product

• 5333-34-6 3-(3,4-dimethoxybenzoyl)propionic acid 
• 98799-43-0 trans-4-(3,4-dimethoxyphenyl)but-3-enoic acid 
• 124-38-9 carbon dioxide 
• 3945-85-5 1-bromo-3-(3,4-dimethoxyphenyl)propane 
• 91-16-7 1,2-dimethoxybenzene 
• 3929-47-3 3-(3,4-dimethoxyphenyl)-1-propanol 
• 2107-70-2 3,4-methoxycinnamic acid 
• 121213-49-8 9-((CH₂)3(C₆H₄)(OMe)2)-9-borabicyclo{3.3.1}nonane 
• 93-15-2 1,2-dimethoxy-4-(2-propenyl)benzene 
• 137744-82-2 C₁₂H₁₄O₄ 
• 231935-01-6 ethyl 4-(3,4-dimethoxyphenyl)butanoate 
• 5703-21-9 3,4-dimethoxyphenylacetaldehyde 
• 93-40-3 (3,4-Dimethoxyphenyl)acetic acid 
• 348143-75-9 4-(3,4-dimethoxyphenyl)butanoic acid chloride 

Downstream Products

• 231935-01-6 ethyl 4-(3,4-dimethoxyphenyl)butanoate 
• 56880-86-5 4-(3,4-dimethoxyphenyl)butan-1-ol 
• 56242-82-1 4-(2-chloro-4,5-dimethoxyphenyl)butyric acid 
• 54549-75-6 6,7-dihydroxy-3,4-dihydro-1(2H)-naphthalenone 
• 802985-69-9 4-(2-bromo-4,5-dimethoxy-phenyl)-butyric acid 
• 13575-75-2 6,7-dimethoxy-1-oxo-1,2,3,4-tetrahydronaphthalene 
• 348143-75-9 4-(3,4-dimethoxyphenyl)butanoic acid chloride 
• 14335-78-5 5-(3,4-dimethoxyphenyl)-oxa-cyclopentan-2-one 
• 946412-71-1 4-(3,4-dimethoxyphenyl)-1-(4-methoxyphenyl)butan-1-ol 
• 946412-72-2 1-(4-chlorophenyl)-4-(3,4-dimethoxyphenyl)butan-1-ol 
• 946412-73-3 1-(3,4-dichlorophenyl)-4-(3,4-dimethoxyphenyl)butan-1-ol 
• 946412-75-5 1-(1,3-benzodioxol-5-yl)-4-(3,4-dimethoxyphenyl)butan-1-ol 
• 221158-41-4 4-(3,4-dimethoxyphenyl)-1-phenylbutan-1-one 
• 946412-76-6 4-(3,4-dimethoxyphenyl)-1-(4-methylphenyl)butan-1-one 

Relevant articles and documents

Identification of First-in-Class Inhibitors of Kallikrein-Related Peptidase 6 That Promote Oligodendrocyte Differentiation

Multiple sclerosis (MS) is an autoimmune demyelinating disease of the central nervous system (CNS) that causes severe motor, sensory, and cognitive impairments. Kallikrein-related peptidase (KLK)6 is the most abundant serine protease secreted in the CNS, mainly by oligodendrocytes, the myelin-producing cells of the CNS, and KLK6 is assumed to be a robust biomarker of MS, since it is highly increased in the cerebrospinal fluid (CSF) of MS patients. Here, we report the design and biological evaluation of KLK6's low-molecular-weight inhibitors, para-aminobenzyl derivatives. Interestingly, selected hit compounds were selective of the KLK6 proteolytic network encompassing KLK1 and plasmin that also participate in the development of MS physiopathology. Moreover, hits were found noncytotoxic on primary cultures of murine neurons and oligodendrocyte precursor cells (OPCs). Among them, two compounds (32 and 42) were shown to promote the differentiation of OPCs into mature oligodendrocytes in vitro constituting thus emerging leads for the development of regenerative therapies.

-

-

Highly enantioselective [3+2] coupling of cyclic enamides with quinone monoimines promoted by a chiral phosphoric acid

Enantioselective [3+2] coupling of cyclic enamides with quinone monoimines was realised using a chiral phosphoric acid as a catalyst. This transformation allowed for the synthesis of highly enantioenriched polycyclic 2,3-dihydrobenzofurans (up to 99.9% ee). The absolute configuration of one product was determined by an X-ray crystal structural analysis. We also found a possible mechanism for this reaction.